In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of BridgeBio Pharma Inc (NASDAQ: BBIO) closed at $24.87 in the last session, down -2.47% from day before closing price of $25.50. In other words, the price has decreased by -$2.47 from its previous closing price. On the day, 1.69 million shares were traded. BBIO stock price reached its highest trading level at $25.73 during the session, while it also had its lowest trading level at $24.745.
Ratios:
We take a closer look at BBIO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.59 and its Current Ratio is at 4.59.
On January 31, 2024, BMO Capital Markets started tracking the stock assigning a Market Perform rating and target price of $37.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $58.Wells Fargo initiated its Overweight rating on December 08, 2023, with a $58 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 04 ’24 when Scott Randal W. sold 1,500 shares for $31.30 per share. The transaction valued at 46,950 led to the insider holds 4,000 shares of the business.
Scott Randal W. sold 1,000 shares of BBIO for $28,843 on Jun 03 ’24. The Director now owns 5,500 shares after completing the transaction at $28.84 per share. On Mar 01 ’24, another insider, Scott Randal W., who serves as the Director of the company, sold 2,500 shares for $34.00 each. As a result, the insider received 85,000 and left with 6,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 4676380672 and an Enterprise Value of 5968716288. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.34. Its current Enterprise Value per Revenue stands at 27.239 whereas that against EBITDA is -12.019.
Stock Price History:
Over the past 52 weeks, BBIO has reached a high of $44.32, while it has fallen to a 52-week low of $21.62. The 50-Day Moving Average of the stock is -7.03%, while the 200-Day Moving Average is calculated to be -17.69%.
Shares Statistics:
According to the various share statistics, BBIO traded on average about 1.90M shares per day over the past 3-months and 1307530 shares per day over the past 10 days. A total of 175.08M shares are outstanding, with a floating share count of 141.06M. Insiders hold about 24.98% of the company’s shares, while institutions hold 73.17% stake in the company. Shares short for BBIO as of 1721001600 were 21049935 with a Short Ratio of 11.10, compared to 1718323200 on 16661668. Therefore, it implies a Short% of Shares Outstanding of 21049935 and a Short% of Float of 17.23.
Earnings Estimates
The current rating of BridgeBio Pharma Inc (BBIO) reflects the combined expertise of 11.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.49, with high estimates of $2.8 and low estimates of -$1.36.
Analysts are recommending an EPS of between $2.72 and -$4.07 for the fiscal current year, implying an average EPS of -$1.85. EPS for the following year is -$3.04, with 11.0 analysts recommending between -$0.67 and -$4.96.
Revenue Estimates
For the next quarter, 10 analysts are estimating revenue of $205.7M. There is a high estimate of $701.16M for the next quarter, whereas the lowest estimate is $2M.
A total of 11 analysts have provided revenue estimates for BBIO’s current fiscal year. The highest revenue estimate was $912.28M, while the lowest revenue estimate was $211.12M, resulting in an average revenue estimate of $400.09M. In the same quarter a year ago, actual revenue was $9.3MBased on 10 analysts’ estimates, the company’s revenue will be $177.27M in the next fiscal year. The high estimate is $348.34M and the low estimate is $44M.
